HIKAL vs INDOCO: Stock Comparison

Hikal Limited vs Indoco Remedies Limited

Live data: 22 July 2026, 2:52 PM IST • Source: NSE and company filings

Hikal Limited is the larger company by market capitalisation. Hikal Limited shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Hikal Limited and Indoco Remedies Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, HIKAL is more favourable on 11 of 13 scored metrics and INDOCO on 2These counts are context-free and are not an overall rating.

Key Differences

Market Cap
HIKAL is the larger company
₹2,637 Cr vs ₹2,160 Cr
P/E Ratio
HIKAL has a lower P/E
-56.64x vs -23.83x
P/B Ratio
HIKAL has a lower P/B
2.31x vs 2.41x
EPS
HIKAL has higher earnings per share
₹-3.95 vs ₹-10.71
Dividend Yield
HIKAL has a higher dividend yield
0.44% vs 0.08%
Revenue Growth (TTM YoY)
HIKAL has faster revenue growth
37.3% vs 21.9%
EPS Growth (TTM YoY)
HIKAL has faster EPS growth
68.3% vs 0%
Qtr Sales Growth
INDOCO has stronger quarterly sales growth
21.9% vs -5.97%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricHIKALINDOCO
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricHIKALINDOCO
Live Price₹213.81₹233.99
Day Change-4.86%-4.82%
Volume3.47 L71,688
52-Week High₹343.85₹336
52-Week Low₹146.25₹162.19
Distance from 52W High-37.82%-30.36%

Valuation

MetricHIKALINDOCO
Market Cap₹2,637 Cr₹2,160 Cr
P/E Ratio-56.64x-23.83x
P/B Ratio2.31x2.41x
EPS₹-3.95₹-10.71
Book Value₹97.4₹111.55
Dividend Yield0.44%0.08%

Growth

MetricHIKALINDOCO
Revenue Growth (TTM YoY)37.3%21.9%
EPS Growth (TTM YoY)68.3%0%
Qtr Sales Growth-5.97%21.9%
Qtr Profit Growth22.5%39%

Profitability & Leverage

MetricHIKALINDOCO
ROE2.95%-9.42%
ROCE3.52%0.93%
Net Margin-2.88%-5.31%
Operating Margin12.9%7.68%
Debt to Equity0.57x1.16x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricHIKALINDOCO
Promoter Holding68.85%58.86%
FII Holding1.43% 0.87 pp1.27% 0.33 pp
DII Holding7.2% 0.15 pp17.68% 0.47 pp
Public Holding22.52% 0.73 pp22.04% 0.14 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Hikal Limited and Indoco Remedies Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.